Apixaban [2.5 mg and 5 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF)
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 18 April 2023)
The HTA Council recommends the government financing of apixaban [2.5 mg and 5 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with NVAF and subgroups of NVAF patients through their inclusion in the PNF.
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should apixaban [2.5 mg and 5 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with NVAF and subgroups of NVAF patients be funded by the government?
- Secretary of Health Decision: Approved as of 30 June 2023
Evidence and Relevant Documents